MBX Biosciences (MBX) The Citizens Life Sciences Conference 2026 summary

Key announcements and milestones

• Achieved FDA alignment for phase three pivotal study in hypoparathyroidism, maintaining original timelines for initiation and enrollment.

• Phase two results for Kenvuparatide showed a 63% responder rate at 12 weeks, increasing to 79% at six months.

• Phase three will include the intended commercial device and aims to differentiate from once-daily competitors with a once-weekly regimen.

• Obesity portfolio led by MBX 4291, a GLP-1/GIP co-agonist, with a 12-week MAD study readout expected in Q4 for adults with BMI ≥30.

• Funding supports all critical milestones, including phase three completion and pre-commercial activities, with operations funded into 2029 after a recent $87 million ATM sale.

Technology and platform insights

• PEP platform enables programmable prodrugs for steady, prolonged peptide exposure, improving tolerability and convenience.

• Fatty acylation and albumin binding extend peptide circulation time, creating differentiated PK profiles.

• Platform validated by phase two Kenvuparatide results and supports both platform and pipeline company strategy.

• Multi-agonist design expertise, including GLP-1/GIP and triple agonists, addresses unmet needs in tolerability and efficacy.

Clinical program details

• Phase three in hypoparathyroidism: six-month, double-blind, placebo-controlled, composite primary endpoint (serum calcium normalization, no active vitamin D, limited calcium supplement, stable dosing).

• Key secondary endpoint: normalization of urinary calcium, targeting reduction of kidney stone and CKD risk.

• Phase two showed a ~200 mg decrease in urinary calcium for patients with elevated baseline levels.

• One-year follow-up data from phase two Avail study expected in Q2, with high retention and strong physician preference for once-weekly dosing.